Funding for this research was provided by:
Boehringer Ingelheim (PhD Grant)
Received: 7 November 2018
Accepted: 8 May 2019
First Online: 23 May 2019
Ethics approval and consent to participate
: The human RNASeq study has been published before (ArrayExpress E-MTAB-1733) and was approved by the Uppsala Ethical Review Board (Reference #2011/473). The dog, mouse, pig and rat RNASeq data sets have been published before too (GEO GSE43013) - experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Ewha Womans University (No. 2011–03-038,039,062,063 and 065) and Korea Research Institute of Bioscience and Biotechnology (KRIBB-AEC-12005. For the cynomolgus study, all investigations were conducted in accordance with the German Law on the Protection of Animals and performed in accordance with EU guidelines for the accommodation and care of animals used for experimental and other scientific purposes in a facility accredited by the American Association for the Accreditation of Laboratory Animal Care (AAA-LAC). All animals examined were euthanized and routinely necropsied due to natural diseases. Therefore, formal ethics approval was not required in this case.
: All co-authors agreed to publish the study and all included data.
: Boehringer Ingelheim is a research oriented pharmaceutical company. There are no further conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.